Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Clinical Lymphoma, Myeloma & Leukemia|December 13, 2021
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) GroupMauricette Michallet, Mohamad Sobh, Stephane Morisset, et al.
Blood|August 19, 2021
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapyRaphael Itzykson, Elise Fournier, Céline Berthon, et al.
Haematologica|May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND studyGabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
EMBO Molecular Medicine|November 15, 2023
LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibitionSarah Proteau, Imène Krossa, Chrystel Husser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 StudyRathana Kim, Yves Chalandon, Philippe Rousselot, et al.
The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2022
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life ExperienceVincent Marmouset, Justine Decroocq, Sylvain Garciaz, et al.
Haematologica|April 20, 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 studyAlexis Talbot, Arthur Bobin, Léa Tabone, et al.
Pageof 5